Tinnitech International is an Italian innovative start-up founded by an high-profile group of investors and managers who have developed the first “synchronous multimodal therapy” to treat tinnitus with a multi-purpose, effective and long-lasting method.
New Acufree:
The updates for 2025
New Acufree:
The updates for 2025
Request information
Recommended treatment
Successes and improvements 2024
About Us
Development
Innovative medical device with 3 active elements for the treatment of Tinnitus.
Safety
Accuracy and effectiveness of specific electromagnetic fields, applied to the auditory organ under proven harmlessness.
Results
Progressive reduction in the intensity of perceived symptoms, and progressive increase in the duration of relief obtained with Acufree.
Acufree
The non-invasive and customizable remedy that works by reducing the effects of tinnitus.
Acufree, unlike current onerous treatments that do not achieve prolonged reduction of the disorder, achieves a progressive and lasting remedy to tinnitus complaints. Tinnitus, or tinnitus, is an auditory disorder consisting of noises (whistling, buzzing, rattling, pulsating, etc.) that occur at different intensities and tend to intensify over time, eventually becoming chronic, impairing quality of life.
Acufree, has demonstrated in certified clinical trials that it can improve on the results so far in the battle against tinnitus by achieving symptom reduction and prolongation of beneficial effects even after 1 year.
Hence the claim of “progressive and lasting remedy to tinnitus disorders.”
Learn more
The Situation
Tinnitus: around the world, every day, millions of people suffer a loss of quality of life due to this complex, multiple-origin, partially unknown, hitherto incurable condition.
Total World about 750 Million (NB. data not including occasional tinnitus phenomena).
Europe
78
million / 764 million
Australia
5
million / 25 million
Latin America
178
million / 642 million
Africa
89
million / 1.2 billion
U.S.A.
39
million / 329 million
China
146
million / 1.4 billion
Asia
177
million / 4.5 billion
India
38
million / 1.3 billion
Intellectual Property
The technology developed by our company is supported by an “intellectual property portfolio.”Tinnitech INT has a policy of extensive patent coverage of its research, technology and product.
Technology
Tinnitech INT’s innovative Anti-ACUFENI treatment uses cutting-edge electronics that through the integration of auditory, inductive and capacitive tools triggers beneficial effects, both physiological and psycho-perceptive.
The combined delivery of these active elements develops effective synchronous multimodal therapy.
Meetings with the expert:
Every Tuesday from 3 p.m. to 7 p.m.
For information on the operation of ACUFREE or treatment features.
call the 3398105551
Headquarters
Tecnopolo Romano – c/o Innova Incubator Via G. Peroni 386 – 00131 Rome
Northern Italy Headquarters
c/o Ecupharma SRL Via Newton 9a – 20016 Pero, Milan
Direct telephone
+39 3355273686
Administration
06/ 40040358
